Efficacy of ursodezoxycolic acid in the treatment of non-alcoholic fatty liver disease
https://doi.org/10.21518/2079-701X-2018-3-54-59
Abstract
Non-alcoholic fatty liver disease (NAFLD) becomes gradually the most frequent liver disease in the world. Expert teams in the USA, Western Europe, and Russia give pride of place within the NAFLD treatment regime to lifestyle modification including the optimization of physical activity, diet and, as a consequence, the BMI reduction. However, it is often difficult for the practitioner to motivate the patients to change their lifestyle and eating habits. Due to this, it is extremely important to use a pharmacologic therapy aimed at weight loss, reducing insulin resistance and repopulating the severely damaged liver parenchyma. By now ursodeoxycholic acid drugs (Ursosan) have been proved to be highly effective in treating NAFLD in clinical practice, having a significant impact on several pathogenetic mechanisms of this disease.
About the Authors
D. T. Dicheva
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
E. I. Kuznetsova
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
T. A. Baeva
Central Clinical Hospital of Ministry of Internal Affairs of Russia
Russian Federation
Russian Federation
References
1. Maev IV, Andreev DN, Dicheva DT, Kuznetsova EI. Nonalcoholic fatty liver disease. Clinical hepatology, manual for practitioners. Moscow, 2017.
2. Clemente MG, Mandato C, Poeta M, Vajro P. Pedia tric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol, 2016, 22(36): 8078-93.
3. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe. A Review of available epidemiological data. European Association for the Study of the Liver 2013. J Hepatol, 2013, 58: 593–608.
4. Park S, Jeon, WK, Kim, SH et al. Prevalence and risk factors of nonalcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol, 2006, 21: 138–143.
5. Fan JG, Farrell GC. Epidemiology of nonalcoholic fatty liver disease in China. J Hepatol, 2009, 50: 204–210.
6. Hashimoto, E, Tokushigie, K. Prevalence, gender, ethnic variation, and prognosis of NASH. J Gastroenterol, 2011, 46: 63–69.
7. Wong VW, Chu WC, Wong GL et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut, 2012 Mar, 61(3): 409-15.
8. Andreev DN, Maev IV, Dicheva DT, Kuznetsova EI. Diagnosis and treatment of non-alcoholic fatty liver disease: an overview of the European guidelines in 2016. Consilium Medicum, 2017, 19 (8): 8-13.
9. Fan JG, Peng YD. Metabolic syndrome and nonalcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int, 2007, 6: 572–578.
10. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64(1): 73-84.
11. Maev IV, Andreev DN. Non-alcoholic fatty liver disease: mechanisms of development, clinical forms and pharmaceutical correction. Gastroenterologiya. Appendix to the Journal Consilium Medicum, 2012, 2: 36-39.
12. Maev IV, Kuznetsova EI, Andreev DN, Dicheva DT. Modern and perspective approaches to the diagnosis of non-alcoholic fatty liver disease. Consilium Medicum, 2015, 17 (8): 20-7
13. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatology, 2013, 58: 1007–1019.
14. Kazyulin AN. A role of ursodeoxycholic acid in the therapy for nonalcoholic fatty liver disease at different stages of the disease: steatosis, steatohepatitis, fibrosis/cirrhosis. RMJ, 2017, 17: 1248-1257
15. Maev IV, Vyukinova ES, Lebedeva EG, Gvintovkina TO. Pathogenetic therapy of chronic liver diseases induced by metabolic disorders. Farmateka, 2012, 2: 91-95
16. Ermolova TV, Ermolov SYu, Belyaeva EL. Non-alcoholic fatty liver disease: a modern view of the problem. Sovremennaya Farmakoterapiya. 2016, 37: 26-25
17. Nozaki Y, Fujita K, Yoneda M et al. Long-term combination therapy of ezetimibe and acarbose for nonalcoholic fatty liver disease. J Hepatol, 2009, 51: 548–556.
18. Park H, Shima T, Yamaguchi K et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol, 2011, 46: 101–107.
19. Harrison SA, Torgenson S, Hayashi P et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol, 2003, 98: 2485–2490.
20. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG et al: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 2009, 301: 39-51.
21. Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T: Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ, 2010, 341: 5702.
22. Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther, 2004, 20: 23–28.
23. Haukeland JW, Konopski Z, Eggesbo HB et al. Metformin in patients with nonalcoholic fatty liver disease: A randomized, controlled trial. Scand J Gastroenterol, 2009, 44: 853–860.
24. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab, 2012, 97(7): 2347-53.
25. Belfort R, Harrison SA, Brown K, Darland C, Finch J et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med, 2006, 355: 2297– 2307.
26. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the rand-omized placebo-controlled Fatty Liver Improve ment with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology, 2008, 135: 100–110.
27. Aithal GP, Thomas JA, Kaye PV et al. Randomized, placebo controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 2008, 135: 1176–1184.
28. Maev IV, Kucheryavy YuA, Morozov SV. The impact of ursodeoxycholic acid as a monotherapy and in combination with lactulose on the biochemical parameters of the blood of patients with non-alcoholic steatohepatitis. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii i Koloproktoologii, 2013, 1: 31-51
29. Ivashkin VT, Maevskaya MV, Pavlov CH, Tikhonov IN, Shirokova EN, Bueverov AO, Drapkina OM, Shulpekova YuO, Tsukanov VV, Mammayev SN, Maev IV, Palgova LK. Clinical guidelines on the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Association for the Study of the Liver and the Russian Gastroenterological Association. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii i Koloproktoologii, 2016, 2: 24-42
30. Lassailly G, Caiazzo R, Buob D et al. Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients. Gastroenterology, 2015, 149: 377–388.
31. Andreev DN, Dicheva DT, Kuznetsova EI, Maev IV. Non-alcoholic fatty liver disease: treatment from the perspective of evidence-based medicine. Lechaschiy Vrach, 2017, 2: 45-8
Review
For citations:
Dicheva DT, Kuznetsova EI, Baeva TA. Efficacy of ursodezoxycolic acid in the treatment of non-alcoholic fatty liver disease. Meditsinskiy sovet = Medical Council. 2018;(3):54-59. (In Russ.) https://doi.org/10.21518/2079-701X-2018-3-54-59
Views:
846
Email this article 